Therapeutic approaches targeting oncogenic viruses

Prophylactic Vaccines - Prevention Power-Up

• Human Papillomavirus (HPV) Vaccine (e.g., Gardasil 9):
  • Targets high-risk oncogenic types (16, 18, 31, 33, 45, 52, 58) & wart-causing types (6, 11).
  • Prevents cervical, anogenital, and oropharyngeal cancers.
  • Mechanism: Recombinant L1 capsid proteins form non-infectious Virus-Like Particles (VLPs), inducing potent neutralizing antibodies.
• Hepatitis B Virus (HBV) Vaccine:
  • Crucial for preventing Hepatocellular Carcinoma (HCC).
  • Mechanism: Contains recombinant Hepatitis B surface antigen (HBsAg) to stimulate protective anti-HBs antibodies.

⭐ The HPV vaccine is purely prophylactic; it prevents new infections but does not treat existing HPV or related neoplasia.

Antiviral Agents - Viral Eradication

• Goal: Reduce viral load, prevent replication, and decrease cancer risk. Complete eradication is the aim but not always achieved.

• Hepatitis B Virus (HBV):

  • Agents: Tenofovir, Entecavir (NRTIs).
  • Mechanism: Inhibit viral reverse transcriptase.
  • Outcome: Lifelong viral suppression, not a cure. Significantly lowers Hepatocellular Carcinoma (HCC) risk.

• Hepatitis C Virus (HCV):

  • Agents: Direct-Acting Antivirals (DAAs) like Sofosbuvir/Ledipasvir.
  • Mechanism: Target specific viral proteins (e.g., NS5A/NS5B).
  • Outcome: Cure rates >95% (Sustained Virologic Response).

• HPV & EBV:

  • No curative antiviral therapy for latent infection; management focuses on prevention (HPV vaccine) or treating lesions/cancer.

⭐ Sustained Virologic Response (SVR) after DAA therapy for HCV is considered a cure and is associated with a >70% reduction in HCC incidence.

Immunotherapy - Unleashing the Host

• Immune Checkpoint Inhibitors (ICIs): Reinvigorate exhausted T-cells to attack virus-infected tumor cells.
  • PD-1/PD-L1 Inhibitors: Block the "off switch" on T-cells. Used in Merkel cell carcinoma (polyomavirus) & EBV-associated gastric cancer.
    • Examples: Pembrolizumab, Nivolumab.
  • CTLA-4 Inhibitors: Target another T-cell inhibitory receptor.
    • Example: Ipilimumab.
• Therapeutic Vaccines: Stimulate a de novo T-cell response against viral antigens (e.g., HPV E6/E7 oncoproteins).
  • Goal: Break immune tolerance to established infections and associated cancers.
• Adoptive Cell Therapy (CAR-T): Genetically engineer a patient's T-cells to express Chimeric Antigen Receptors (CARs) targeting viral antigens on tumor cells (e.g., EBV-positive lymphomas).

⭐ High-Yield: Many oncogenic viruses (e.g., EBV, KSHV) induce chronic inflammation and exploit the PD-1/PD-L1 pathway to cause T-cell exhaustion, hiding the tumor from the immune system. ICIs restore this lost surveillance.

Targeted Cellular Therapies - Hacking the Hijack

• Concept: Genetically engineering a patient's own T-cells to specifically recognize and kill cancer cells expressing viral antigens. This offers high specificity, minimizing off-tumor effects.

• Chimeric Antigen Receptor (CAR)-T Cells:

  • Engineered to express synthetic receptors (CARs).
  • Recognize viral proteins on the tumor cell surface (MHC-independent).
  • Example: Targeting EBV's LMP1/LMP2 in nasopharyngeal carcinoma.

• T-Cell Receptor (TCR)-T Cells:

  • Engineered to express specific TCRs.
  • Recognize processed viral peptides presented by MHC molecules.
  • Can target intracellular antigens (e.g., HPV E6/E7, EBV EBNA1).
  • MHC-restricted, requiring HLA matching.

⭐ High-Yield: Unlike conventional cancer antigens, viral antigens are truly tumor-specific. This makes therapies like CAR-T/TCR-T targeting viral proteins (e.g., HPV E6/E7) highly precise with a lower risk of attacking healthy host cells.

High‑Yield Points - ⚡ Biggest Takeaways

• Prophylactic vaccination is the primary prevention for cancers caused by HPV and HBV.
• Treating chronic HCV/HBV with antivirals lowers hepatocellular carcinoma risk.
• For EBV and KSHV, treatment targets the malignancy itself (e.g., lymphoma, sarcoma), not the latent virus.
• Immune checkpoint inhibitors are effective for cancers like Merkel cell carcinoma (MCPyV) and cervical cancer.
• Restoring immunity is crucial for Kaposi's sarcoma in HIV/AIDS.
• Screening (e.g., Pap smear) is key for early detection.